Related Experiment Videos
Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment
Matthew T Roe1, Eric D Peterson, Yun Li
1Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA. roe00001@mc.duke.edu
Insights
Any troponin elevation in non-ST-segment elevation acute coronary syndromes (NSTE ACSs) increases mortality risk. However, guideline therapies are underused in mild elevations, while invasive procedures are more common in those with troponin levels below the reference limit.
Area of Science:
- Cardiology
- Biomarkers
- Clinical Decision Making
Background:
- The clinical significance of troponin elevation thresholds in non-ST-segment elevation acute coronary syndromes (NSTE ACSs) remains unevaluated.
- Establishing these thresholds is crucial for guiding clinical decision-making and risk stratification.
Purpose of the Study:
- To evaluate the impact of different troponin elevation thresholds on clinical decision-making and patient outcomes in NSTE ACSs.
- To determine if current treatment strategies align with troponin levels in NSTE ACS patients.
Main Methods:
- Analysis of 23,298 patients with NSTE ACSs from the CRUSADE initiative.
- Categorization of patients based on maximum troponin ratios within 24 hours relative to the upper limit of normal (ULN).
Main Results:
- In-hospital mortality rates increased with higher troponin ratios (0-1x ULN: 2.8% to >5x ULN: 6.0%).
- Guideline-recommended medical therapies were used more frequently in patients with intermediate and major troponin elevations.
- Patients with troponin levels below the reference limit underwent invasive procedures more often than those with minor elevations.
Conclusions:
- All levels of troponin elevation in NSTE ACS are linked to increased mortality risk.
- Treatment patterns, including medical therapies and invasive procedures, do not consistently align with troponin elevation levels across all patient groups.
Background:
The threshold of troponin elevation that stimulates changes in clinical decision making for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACSs) has not been previously evaluated.
Methods:
A total of 23 298 patients with NSTE ACSs from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) initiative were separated into categories of maximum troponin ratios (ratio of the highest recorded troponin value in the first 24 hours to the local laboratory troponin assay upper limit of normalization [ULN]).
Results:
Unadjusted rates of in-hospital mortality increased from the group with troponin levels below the reference limit (maximum troponin ratio 0-1 x ULN; n = 5291) to those with minor (1-2 x ULN; n = 2499), intermediate (2-5 x ULN; n = 3825), and major (>5 x ULN; n = 11 683) elevations (-2.8% vs 4.6% vs 4.7% vs 6.0%). The use of early (<24 hours) aspirin, heparin, glycoprotein IIb/IIIa inhibitors, and beta-blockers was similar for the group with troponin levels below the reference limit compared with those with minor troponin elevations, and greater use of medications was demonstrated in patients with intermediate and major troponin elevations. Use of cardiac catheterization and percutaneous coronary intervention was higher in patients with troponin levels below the reference limit compared with those with minor troponin elevations, and procedures were used most frequently in patients with major troponin elevations. Similar patterns of care were demonstrated after excluding patients with chronic renal insufficiency.
Conclusions:
Any degree of troponin elevation is associated with a higher risk of mortality for patients with NSTE ACSs, but guideline-recommended medical therapies are used more commonly only in patients with intermediate and major troponin elevations, whereas patients with troponin levels below the reference limit underwent invasive procedures more frequently than those with mild troponin elevations.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...